SCHEMBL25700617

SCHEMBL25700617

Cn1cc(S(=O)(=O)NCc2ccc(F)cc2)ccc1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.57
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57
▸ CA9 Q16790 1/20 0.57
▸ PKM P14618 1/20 0.52
▸ CYP19A1 P11511 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ POLB P06746 4/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ THRB P10828 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ BAZ2B Q9UIF8 1/20 0.49
▸ LMNA P02545 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ GNRHR P30968 1/20 0.47
▸ DUSP3 P51452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27950175 0.76 CA9 (0.71) KMT2ACA1CA2CA9CYP19A1
SCHEMBL13972679 0.74 CA1 (0.68) KMT2ACA1CA2CA9PKM
SCHEMBL20946426 0.73 CA1 (0.77) KMT2ACA1CA2CA9PKM
SCHEMBL7507787 0.73 CA1 (0.71) KMT2ACA1CA2CA9PKM
SCHEMBL13959180 0.72 CA1 (0.66) CA1CA2CA9PKMCYP19A1
SCHEMBL1893565 0.72 ALDH1A1 (0.76) CA1CA2CA9PKMCYP19A1
SCHEMBL6289448 0.72 CYP19A1 (0.78) KMT2ACA1CA2CA9CYP19A1
SCHEMBL4663044 0.72 KEAP1 (0.76) KMT2ACA1CA2CA9PKM
SCHEMBL25700619 0.72 CNR2 (0.51) KMT2APOLBALDH1A1LMNARECQL
SCHEMBL17979485 0.71 THRB (0.50) KMT2ACA1CA2CA9CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 — — WO disclosed
Send feedback